| 黄 莉,鲁利群,黄 鸿,周 琴,杨 欣.沐舒坦联合布地奈德雾化治疗新生儿胎粪吸入综合征的临床应用分析[J].,2020,(13):2593-2596 |
| 沐舒坦联合布地奈德雾化治疗新生儿胎粪吸入综合征的临床应用分析 |
| Clinical Application of Mucosolvan Combined with Budesonide for the Neonatal Meconium Inhalation Syndrome |
| 投稿时间：2019-12-07 修订日期：2019-12-30 |
| DOI：10.13241/j.cnki.pmb.2020.13.042 |
| 中文关键词: 沐舒坦 布地奈德 新生儿胎粪吸入综合征 临床疗效 预后 |
| 英文关键词: Mucosolvan Budesonide Neonatal meconium aspiration syndrome Clinical efficacy Prognosis |
| 基金项目:四川省医学会科研项目(S18011) |
|
| 摘要点击次数: 702 |
| 全文下载次数: 506 |
| 中文摘要: |
| 摘要 目的：探讨沐舒坦联合布地奈德雾化治疗新生儿胎粪吸入综合征的临床效果及安全性。方法：选择2017年1月~2018年2月我院新生儿科收治的76例新生儿胎粪吸入综合征患儿，按照随机数字表法将其分成两组，每组38例。对照组患者采用布地奈德雾化治疗，观察组在对照组的治疗基础上加用沐舒坦治疗，分析和比较两组的治疗效果，患儿治疗前后动脉血气分析指标变化以及预后情况。结果：治疗后，观察组临床总有效率明显高于对照组，观察组呼吸困难缓解时间、肺部湿罗音消失时间、发绀消失时间、血氧饱和度恢复时间均显著较对照组短(P<0.05)。两组患儿治疗后PaCO2、FIO2、OI均较治疗前降低，PaO2均较治疗前上升，其中观察组PaCO2、FIO2、OI明显低于对照组，PaO2高于对照组，上述差异均具有统计学意义(P<0.05)。观察组总并发症发生率显著低于对照组(P<0.05)，患儿治愈率显著高于对照组(P<0.05)，两组死亡率比较差异无统计学意义(P＞0.05)。结论：与布地奈德雾化治疗相比，沐舒坦联合布地奈德雾化治疗新生儿胎粪吸入综合征患儿可以更有效缩短临床症状改善时间，改善患儿肺功能及预后，且安全性更高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect and safety of mucosolvan combined with budesonide atomization in the treatment of meconium aspiration syndrome in newborns. Methods: From January 2017 to February 2018, 76 cases of neonatal meconium aspiration syndrome were treated in the Department of Neonatology of our hospital. The patients were divided into two groups according to the random number table method, 38 cases in each group. The patients in the control group were treated with budesonide atomization, while the patients in the observation group were treated with Mucosolvan on the basis of the treatment in the control group. Analysis and comparison of the therapeutic effects of the two groups, the changes of arterial blood gas analysis indexes and the prognosis in children before and after treatment. Results: After treatment, the total clinical effective rate of the observation group was significantly higher than that of the control group. The relief time of dyspnea, the disappearance time of moist rales in lungs, the disappearance time of cyanosis and the recovery time of oxygen saturation in blood were significantly shorter than those of the control group (P<0.05). After treatment, the PaCO2, FIO2 and OI of the two groups were all lower than those before treatment, and PaO2 was all lower. Compared with before treatment, PaCO2, FIO2 and OI in the observation group were significantly lower than those in the control group, and PaO2 was higher than that of the control group, the above differences were statistically significant (P<0.05). The incidence of total complications in the observation group was significantly lower than that in the control group (P<0.05); the cure rate in the observation group was significantly higher than that in the control group (P<0.05), there was no significant difference in mortality between the two groups (P>0.05). Conclusion: Compared with Budesonide aerosol therapy, Mucosolvan combined with budesonide atomization in the treatment of neonatal meconium aspiration syndrome can shorten the improvement time of clinical symptoms. improve pulmonary function and prognosis, and has higher safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
